Olmesartan (Benicar)
What studies of Olmesartan (Benicar) found
At a glance, by condition
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for overall symptoms.
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Olmesartan (Benicar) might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Olmesartan (Benicar) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Daily life and health overall
Overall symptoms1 study Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.
Studies with no comparison group1 study · 40 mg, every 4–8 h (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of olmesartan (Benicar) on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people, or how many isn't reported
- Not all results were tested against chance
See the 1 study
-
Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis. (2013)
- People in the study
- —
- Dose
- 40 mg, every 4–8 h
- Outcome
- time to recover
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
Stopping because of side effects1 study
some patients have reported that their immunopathology is simply too strong to tolerate, and they have also stopped therapy or decided to take a break
Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis. (2013)
Side effects studies reported1 kind
| Side effect | Studies that reported it |
|---|---|
| Worse symptoms or a flare | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
40 mg at the start
- 2Top dose
Most often 40 mg (1 of 1 studies)
Doses across 1 study
40 to 40 mg.
Each study’s dose, as printed
- 40 mg, every 4–8 h Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis. (2013)